Troriluzole is an experimental medication that has been investigated as a potential treatment for Machado–Joseph disease (MJD), obsessive–compulsive disorder (OCD), and glioblastoma. It is a prodrug modification of the medication riluzole.

Pharmacology

Pharmacokinetics

While riluzole is typically taken twice-daily and on an empty stomach, troriluzole may offer a potential once-daily dosing with or without food along with greater bioavailability.

Research

In 2024, researchers published a study in the Journal of Neurochemistry that reported troriluzole could reverse some early Alzheimer's disease brain changes in mice, reduce harmful glutamate levels, and improve memory and learning abilities.